## CONTENTS

**ACKNOWLEDGMENTS** ix

**INTRODUCTION** 1

**CHAPTER 1  THE FOUR SECRETS THE DRUG COMPANIES DON’T WANT YOU TO KNOW** 4
- Drug Companies Underestimate Dangerous Side Effects 5
- Drug Companies Control Much of the Information Your Doctor Gets 10
- You’re Often Prescribed Drugs That You Don’t Need 14
- Drugs Target the Symptoms, Not the Cause 19
- Conclusion 22
- References 23

**CHAPTER 2  WHAT HAS HAPPENED TO R&D PRODUCTIVITY?** 25
- Impact of Mergers on R&D Productivity 26
- Heightened FDA Requirements for NDAs 34
- Higher Hurdles Set by Payers 41
- Conclusion 46
- References 48

**CHAPTER 3  KEY THERAPEUTIC AREAS FOR IMPROVING HEALTH** 49
- Cancer 51
- Diseases of the Brain 54
- Cardiovascular Disease (CVD) 60
- Diabetes 63
- Bacterial Infections 65
- Conclusion 68
- References 69

**CHAPTER 4  IMPROVING R&D OUTPUT** 71
- The Views of Others 72
  - Pharma’s Blockbuster Mentality Needs to Change 72
  - Can “Predictive Innovation” Lead to Greater Success Rates? 76
  - Would Royalties Make Scientists More Productive? 78
  - Will Drug Repositioning Help Fill the R&D Pipeline? 80
  - Consultants Don’t Always Have the Facts 82
- Personal Views 84
  - Discovery Must Focus on Productivity 85
  - Does Size Help or Hinder R&D Productivity? 87

**REFERENCES**
## CONTENTS

- To Outsource or Not to Outsource? That’s the Pharma R&D Question 89
  - Big Pharma Early Research Collaborations 92
  - Conclusion 93
  - References 95

### CHAPTER 5  RESTORING PHARMA’S IMAGE 96

- Illegal Detailing of Drugs 97
- Pharmaceutical Companies Should Drop TV Ads 98
- The Need for Greater Transparency 100
- How Committed Is Big Pharma to Rare Diseases? 102
- Pharmaceutical Companies and Philanthropy 104
- Pharma Needs to Have Its Scientists Tell Their Stories 105
- Conclusion 106
- References 107

### CHAPTER 6  FINAL THOUGHTS 109

- References 114

## INDEX 115